17 alpha-hydroxyprogesterone caproate has been researched along with Invasiveness, Neoplasm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dyba, T; Karolewski, K; Klimek, M; Kojs, Z; Urbański, K | 1 |
1 trial(s) available for 17 alpha-hydroxyprogesterone caproate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brachytherapy; Carcinoma; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Prognosis; Proportional Hazards Models; Prospective Studies; Radioisotope Teletherapy; Survival Rate; Treatment Outcome | 1993 |